Durvalumab and tremelimumab with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.

Sehhoon ParkDongryul OhYoon-La ChoiSang Ah ChiKyunga KimMyung-Ju Ahn Jong-Mu Sun

Published in: Cancer (2022)

Durvalumab and tremelimumab with definitive CCRT had promising efficacy in patients with locally advanced ESCC. In addition, PD-L1 expression had strong predictive value in the study population.

Keyphrases

locally advanced
rectal cancer
neoadjuvant chemotherapy
squamous cell carcinoma
radiation therapy
phase ii study
clinical trial
lymph node
double blind